The authors review current and novel treatments for patients with HAE.
H ereditary angioedema (HAE) is a rare autosomal dominant disorder resulting from deficiency of C1 inhibitor (C1 INH) protein or function. Individuals with HAE undergo "attacks," or episodic swelling, which most often affect the skin of the extremities or the mucosal tissues of the upper respiratory and gastrointestinal tracts.
The disease is caused by a mutation in the gene-encoding C1 INH protein located on chromosome 11. C1 INH, a serine protease inhibitor (serpin), is a primary regulator of the complement and kinin systems. Deficiency of C1 INH leads to unregulated activation of bradykinin. Data from various studies [1] [2] [3] indicate that bradykinin plays an important role in mediating HAE symptoms such as pain and vascular permeability changes that lead to edema.
Two main types of HAE, type I and type II, account for the majority of HAE cases. Type I HAE (found in approximately 80%-85% of patients with HAE) is characterized by low levels of C1 INH. Type II HAE (found in 15%-20% of patients with HAE) is characterized by normal or elevated levels of dysfunctional C1 INH. 4, 5 A newer subtype of HAE, type III, has been described within the past decade. In some patients, type III HAE is characterized by X-linked dominant inheritance. 6 It is more common in female individuals, but it has also been identified in male individuals. Both estrogen-dependent and estrogen-independent forms of type III HAE have been described. Type III HAE is not associated with C1 INH deficiency, but it manifests with symptoms similar to those of types I and II. Some cases of type III HAE are associated with genetic defects involving factor XII (Hageman factor). 6 Type I and type HAE attacks was restricted to supportive measures such as intravenous fluids administration and pain management. Corticosteroids, epinephrine, and antihistamines have also been used to manage HAE attacks but are not efficacious. 7 Fresh frozen plasma (FFP) has been used to abort attacks because it contains C1 INH, but there is a theoretic concern that FFP can worsen acute edema by supplying substrates involved in the generation of edema. 7 In addition, the risk of blood-borne pathogens is greater with FFP than with human plasma-derived C1
INH, 7 a treatment option that has until recently been unavailable in the United States but that has been used in European countries for many decades. 
Prevalence
Hereditary angioedema is estimated to affect approximately 1 in 50,000 persons, with no ethnic group differences. 7 Attacks of HAE follow an unpredictable pattern.
Anatomical site, frequency, and severity vary among individual patients. Subcutaneous attacks commonly affect the extremities but can affect any part of the body.
In the United States, HAE attacks have been associated with 15,000 to 30,000 emergency room visits annually. 8 Mortality, secondary to laryngeal edema and asphyxiation, has been reported in up to 30% of patients who were previously undiagnosed. 8 Abdominal attacks can lead to hospitalizations and unnecessary surgical procedures. Some patients develop narcotic dependence because of the chronic severe abdominal pain associated with HAE attacks, whereas other patients may require psychiatric care to manage the stress and anxiety associated with their disease preventing them from leading a productive life.
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Standard Treatment Options
Because of the morbidity, mortality, and greatly reduced quality of life associated with HAE, treatment strategies for patients with this disease have been aimed at attack prevention (prophylaxis) and management (on demand) ( Table 2 ).
Until recently, prevention and management options for acute HAE attacks were limited in the United States.
Prophylactic therapy was limited to attenuated androgens and antifibrinolytics, both of which have substantial contraindications and adverse effects. 7 Management of 9 Cinryze is a lyophilized intravenous preparation. This product is nanofiltered to remove viral and potentially prion-sized particles. In addition, it is screened using polymerase chain reaction and then subjected to multiple viral inactivation and removal steps, including pasteurization. 14 The high level of safety of human plasma-derived C1 INH is a result of the multiple steps taken during collection and processing, which reduce the overall risk for blood-borne pathogens. INH. 27 The drug was administered intravenously in doses ranging from 6.25 U/kg to 100 U/kg. There was an increase of plasma level of C4 and an inhibition of complement C4 cleavage. The half-life of rh C1 INH was dose dependent; the longest half-life, of approximately 3 hours, was observed at the dose of 100 U/kg. Because of the short half-life, rh C1 INH is expected to be more effective for the management of HAE attacks than for prophylaxis. Adverse effects were minimal; however, 1 patient with a rabbit allergy developed anaphylaxis secondary to residual rabbit proteins in rh C1 INH. 30 In an open-label, phase II clinical trial, 13 severe angioedema attacks in 9 patients were managed with Rhucin (100 U/kg). 28 The mean time to onset of symptom at any body location in 57 patients. 25 The main study endpoints were time to onset of symptom relief, complete resolution of all symptoms, and safety. The median times to complete resolution of all symptoms were 8 hours for laryngeal attacks, 10 hours for abdominal attacks, 24 hours for peripheral attacks, and 31 hours for facial attacks. 25 To our knowledge, no drug-related serious adverse events have been reported to the FDA or to the drug manufacturer (CSL Behring) to date.
In a clinical study, 23 the most common adverse reactions in participants who received Berinert (ie, those reported in >4% of participants) were headache, abdominal pain, nausea, muscle spasms, pain, diarrhea, and vomiting. 23 Most of these adverse events are thought to be secondary to symptoms related to HAE attacks and not to the medication. The EDEMA4 trial had a study design similar to that of EDEMA3 and involved 96 patients with acute HAE symptoms. 34 The primary endpoint was Mean Symptom
The Berinert that is manufactured in the United
Complex Severity (MSCS) score measured at 4 hours.
The MSCS score is a patient-reported measure that rates severity of symptoms at a specific time on a scale ranging Ecallantide was well tolerated; the most common reported adverse effects were headache, nausea, fatigue, and upper respiratory infections. 33 Hypersensitivity, including anaphylaxis, was also reported. Throughout the study, 10 of 255 patients (3.9%) who received ecallantide developed hypersensitivity that was consistent with anaphylaxis, with all reactions occurring within 60 minutes reactions were reported, and no immunogenic reactions against rh C1 INH or rabbit protein were observed.
In a randomized, double-blind, placebo-controlled phase III study 29 29 The benefits of rh C1
INH are that it carries no risk of transmission of human blood-borne pathogens, and production of the drug can be more easily controlled because it is not dependent on plasma center donors.
Inhibition of Kinin Pathway
Plasma Kallikrein Inhibitor (Ecallantide)
Ecallantide ( No drug-related serious adverse events were reported.
The most common adverse effects reported in the studies were limited to localized, mild erythema and edema at the site of injection and occasional minor burning sensations, itching, or pain, all of which resolved within a few hours.
In the FAST-3 trial, 88 patients with acute HAE attacks who received icatibant had statistically significant improvement in symptom relief compared with patients who received placebo. 40 Phase IV postmarketing surveillance studies to monitor the incidence of these reactions are being conducted. 36 Ecallantide represents a novel treatment option for patients with HAE. The recommended dose of ecallantide to manage an angioedema attack is 30 mg, administered as three 1-mL subcutaneous injections. 32 Maximum ecallantide levels are reached 2 to 3 hours after subcutaneous injection, and the half-life is approximately 2 hours. 
Conclusion
In the past several years, many new therapies have emerged for the prevention and management of HAE attacks. Several additional therapies are likely to be approved in years to come. Introduction of these new therapeutic agents will allow physicians to manage and individualize HAE care appropriately.
